The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Colorectal tumors that are wild-type (WT) for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy(1,2). The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation stands in mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Luis A., Williams, Richard, Wu, Jian, Kinde, Isaac, Hecht, J. Randolph, Berlin, Jordan, Allen, Benjamin, Bozic, Ivana, Reiter, Johannes G., Nowak, Martin A., Kinzler, Kenneth W., Oliner, Kelly S., Vogelstein, Bert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436069/
https://www.ncbi.nlm.nih.gov/pubmed/22722843
http://dx.doi.org/10.1038/nature11219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436069/
https://www.ncbi.nlm.nih.gov/pubmed/22722843
http://dx.doi.org/10.1038/nature11219

Ejemplares similares